Neuroleptic malignant aripiprazole

Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol 2004 19(6) 351-3. 

Fluoxetine and probably paroxetine may cause clinically significant increases in aripiprazole levels. The concurrent use of aripiprazole with SSRIs or venlafaxine has led to adverse effects such as the neuroleptic malignant syndrome and extrapyramidal symptoms. 

The concurrent use of aripiprazole and SSRIs can be useful, but it is important to remember to adjust the dose if paroxetine or fluoxetine are started or stopped, and be aware that, rarely, adverse effects such as extrapyramidal symptoms and the neuroleptic malignant syndrome may develop. 

Duggal HS, Kithas J. Possible neuroleptic malignant syndrome with aripiprazole and fluoxetine./I (2005) 162, 397-8. 

Neuroleptic malignant syndrome has been previously described in association with aripiprazole [SEDA-31, 76 SEDA-33,101], and new cases have been reported [62, 63, 64 ]. 

Patel MK, Brunetti L. Neuroleptic malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient. Am J Health Syst Pharm 2010 67 1254—9. 

Dassa D, Drai-Moog D, Samuelian JC. Neuroleptic malignant syndrome with the addition of aripiprazole to clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2010 34 427-8. 

Gahr M, Orth M, Abler B. Neuroleptic malignant syndrome with aripiprazole in Huntington s disease. Mov Disord 2010 25 2475-6. 

Wei C Yinqiao Pian, 771 nervousness bofutsushosan, 774 Ephedra, 11A liraglutide, 693 nervous system depression chloroform, 195 prilocaine, 216 rupatadine, 274-5 neural tube defects caffeine, 6-7 neurodevelopment delay amiodarone, 294 neuroexdtation pethidine (meperidine), 151 neuroleptic malignant syndrome aripiprazole, 61 lithium, 27... 

Nervous system Aripiprazole has been previously associated with neuroleptic malignant syndrome but with doubts about the validity of the diagnoses. However, postmarketing pharmacovigilance schemes in Australia have collected a higher proportion of cases of neuroleptic malignant syndrome with aripiprazole compared with the total number of reports received for... 

Nervous system Neuroleptic malignant syndrome is described with aripiprazole in an adolescent with a history of impulsive, disorganised and bizarre behaviour [91 ]. 

A 15-year-old male titrated to 20 mg daily of aripiprazole over a 4-week period developed neuroleptic malignant syndrome which was successfully treated with bromocriptine he also showed signs on MRI of posterior reversible encephalopathy syndrome which can be associated with neuroleptic malignant syndrome. 

---